Accessibility Menu
 
Telix Pharmaceuticals logo

Telix Pharmaceuticals

(OTC) TLPPF

Current Price$8.72
Market Cap$2.95B
Since IPO (2019)+700%
5 Year+142%
1 Year-54%
1 Month+29%

Telix Pharmaceuticals Financials at a Glance

Market Cap

$2.95B

Revenue (TTM)

$2.01B

Net Income (TTM)

$39.06M

EPS (TTM)

$-0.02

P/E Ratio

-413.18

Dividend

$0.00

Beta (Volatility)

0.40 (Low)

Price

$8.72

Volume

1,200

Open

$8.93

Previous Close

$8.72

Daily Range

$8.65 - $8.93

52-Week Range

$5.91 - $19.99

TLPPF News

No articles available.

TLPPF: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Telix Pharmaceuticals

Industry

Biotechnology

Employees

234

CEO

Christian P. Behrenbruch, PhD, EMBA

Headquarters

North Melbourne, VIC 3051, AU

TLPPF Financials

Key Financial Metrics (TTM)

Gross Margin

51%

Operating Margin

2%

Net Income Margin

-1%

Return on Equity

-2%

Return on Capital

2%

Return on Assets

-1%

Earnings Yield

-0.24%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.95B

Shares Outstanding

338.89M

Volume

1.20K

Short Interest

0.00%

Avg. Volume

4.24K

Financials (TTM)

Gross Profit

$661.81M

Operating Income

$27.54M

EBITDA

$82.52M

Operating Cash Flow

$26.81M

Capital Expenditure

$58.78M

Free Cash Flow

$85.59M

Cash & ST Invst.

$212.66M

Total Debt

$784.94M

Telix Pharmaceuticals Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$630.70M

+123.9%

Gross Profit

$332.84M

+48.6%

Gross Margin

52.77%

N/A

Market Cap

$2.95B

N/A

Market Cap/Employee

$7.12M

N/A

Employees

415

N/A

Net Income

$7.37M

-137.7%

EBITDA

$29.40M

+27.9%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$572.28M

-640.9%

Accounts Receivable

$207.42M

+220.2%

Inventory

$55.58M

+221.1%

Long Term Debt

$756.97M

+4665.0%

Short Term Debt

$27.97M

+1694.0%

Return on Assets

-0.61%

N/A

Return on Invested Capital

1.81%

N/A

Free Cash Flow

$94.47M

-3426.4%

Operating Cash Flow

$54.35M

-611.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ANSLFAnsell Limited
$22.74+5.54%
CAMRFCamurus AB (publ)
$55.00+0.00%
ULIHFThe United Laboratories International Holdings Limited
$1.33+0.00%
SDGCFSundrug Co.,Ltd.
$28.18+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$171.28-0.04%
NOKNokia
$8.28-0.02%
TSLATesla
$372.24-0.04%
AMDAdvanced Micro Devices
$203.89-0.07%

Questions About TLPPF

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.